U.S. FDA starts to review NDA of SK Biopharmaceuticals’ new sleep disorder treatment

Published: 2018-03-06 16:05:09

Updated: 2018-03-06 16:05:09

SK Biopharmaceuticals(CEO Jung-Woo Cho) announced the company completed the New Drug Application(NDA) of SKL-N05(generic name: solriamfetol) that is being jointly developed with Jazz Pharmaceuticals, the world’s top pharmaceutical company in the sleep disorder market, for approval on December 2017 and the authorities have started to officially review the application.

This means they have succe...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.